Expression of CYR61, CTGF, VEGF-C, VEGFR-2 mRNA in bone marrow of leukemia patients and its clinical significance.
- Author:
Ning XU
1
;
Qi-Tu HE
;
Yan LU
;
Xuan-Mao HAN
;
Hong-Jie MA
;
Dong-Xia ZHANG
;
Xue-Wen LIU
;
Xiao-Jun YUAN
;
Guo-Rong JIA
;
Jing LI
;
Zhe LI
;
Zhi-Qin LI
;
Hai-Yan HAN
Author Information
1. Department of Hematology, Baotou Medical College First Hospital, Baotou, Inner Mongolian Autonomours Region, China.
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adult;
Aged;
Bone Marrow;
metabolism;
Case-Control Studies;
Child;
Connective Tissue Growth Factor;
metabolism;
Cysteine-Rich Protein 61;
metabolism;
Female;
Humans;
Leukemia;
metabolism;
pathology;
Male;
Middle Aged;
RNA, Messenger;
genetics;
Vascular Endothelial Growth Factor C;
metabolism;
Vascular Endothelial Growth Factor Receptor-2;
metabolism;
Young Adult
- From:
Journal of Experimental Hematology
2011;19(6):1368-1373
- CountryChina
- Language:Chinese
-
Abstract:
The study was aimed to detect the levels of CYR61, CTGF, VEGF-C, VEGFR-2 mRNA in bone marrow (BM) of leukemia patients and investigate the interaction of CYR61, CTGF, VEGF-C, VEGFR-2 proteins in occurrence, development, infiltration and metastasis of leukemia and its clinical significance, to find a new tumor marker for diagnosis and treatment of leukemia with some new directions. 74 patients with leukemia were enrolled in this study, 38 out of them were males and 36 were females, aged from 6 to 77 years old with the median age of 45 years old. In the control group, 7 males and 5 females, aged from 16 to 78 years old with the median age of 46. Semi-quantitative reverse transcription polymerase chain reaction (RT-PCR) was used to detect the levels of CYR61, CTGF, VEGF-C, VEGFR-2 mRNA. The results showed that the levels of CYR61, CTGF, VEGF-C, VEGFR-2 mRNA in BM of newly diagnosed patients with acute and chronic leukemia of each group were significantly higher as compared with the control group (p < 0.05). The levels of CYR61, CTGF mRNA in acute leukemia remission group were significantly higher than those in control group (p = 0.039, 0.025). The level of CTGF mRNA was highest in B-ALL group, and was higher than that in AML, CML, CLL, T-ALL groups (p = 0.002, 0.034, 0.002, 0.010). In AML group, mRNA expressions of CYR61 and CTGF, CYR61 and VEGF-C, CTGF and VEGFR-2 were positively correlated (r = 0.452, 0.466, 0.464; p = 0.045, 0.038, 0.039), and in CML group mRNA expression of CYR61 and VEGF-C was positively correlated (r = 0.882, p = 0.000). The expression levels of VEGF-C, VEGFR-2 mRNA in acute leukemia patients with extramedullary infiltration were higher than those in acute leukemia patients without extramedullary infiltration (p = 0.028, 0.047). VEGF-C mRNA expression and the original cell counts in AML group were positively correlated (r = 0.418, p = 0.034). It is concluded that CYR61, CTGF, VEGF-C and VEGFR-2 interact each other in the pathogenesis of leukemia, promote the development, metastasis and infiltration of leukemia; and these factors in different types of leukemia and extramedullary infiltration are different, which may become tumor markers of leukemia; and blocking VEGF-C and VEGFR-2 may block tumor growth and metastasis.
